We studied the effects of administration of TOS , a new growth factor derived from lactose for Bifidobacterium, and Bifidobacterium breve 4006 on the fecal flora of normal subjects. All of the Bifidobacterium species tested , eight reference strains and B. breve 4006 were capable of fermenting TOS in vitro , while others, 2 Bacteroides strains and 4 Lactobacillus and Enterobacteriaceae strains , showed an appreciable growth among 55 cultures tested. It was evident that TOS is not intestinally absorbed by the recipient subjects, from hydrogen breath test . In vivo, TOS (3g or 10g/day) was observed to promote the growth of both administered B. breve 4006 and resident Bifidobacterium strains. Simultaneous administration of B. breve 4006 and TOS caused the suppression of gram negative anaerobes and aerobes, Bacteroidaceae and Enterobacteriaceae , and the reduction of fecal ammonia and urinary indican excretion . It is concluded that TOS is a typical bifidus factor.
It has been recognized that breast-feeding prevents infants from a variety of diarrheal and respiratory infections which are major causes for infantile morbidity and mortality (5, 6) . Extensive studies have shown the significance of anti-infectious factors in breast milk, notably the maternal immune factors and the bifidus factor (13, 23) .
Fecal microbiological examination shows that Bifidobacterium (1010-1011/g of feces) is predominant in the intestine of the breast-fed infants, whereas the bottle-fed infants colonize Bacteroides, Peptostreptococcus, Enterobacteriaceae and Streptococcus to a similar proportion with Bifidobacterium (2, 16, 23) . It is evident that acetic and lactic acid in the colon, produced by the bifidus flora of breastfed infants, are involved in defense mechanisms against gastroenteritis (3) .
Much effort has been made to stimulate the propagation of bifidobacteria in bottlefed infants either by adding bifidus-growth factors or the direct implantation of bifidobacteria. Bifidus-growth factors were reported such as N-acetyl-D-glucosamine (8), lactulose (7, 15) , panthetine (17) , bovine casein hydrolysates (12) and oligosaccharides (25) . However most of the bifidus-growth factors, reported so far, were found to be effective in vitro only, while the in vivo activity of these factors remained obscure or unsatisfactory (4, 9). The present study was undertaken to determine the effects of the administration of transgalactosylated oligosaccharides (TOS), the new bifidus factor, or Bifidobacterium breve 4006 on ecology or metabolism of the fecal flora. The TOS was isolated by the present authors during incidental transfer reactions to a hydrolysis reaction when 
Materials and Methods
Subjects: Sixteen healthy men, ranging from 25 to 35 years of age, were employed in the study. None received medication within 3 weeks before or during the study. Written consent was previously obtained from each subject.
Utilization of TOS in vitro and in vivo: Prior to the feeding experiment with Bifidobacterium breve 4006 and/or TOS, we tested the hypothesis that TOS is exclusively utilized by bifidobacteria in vitro. The ability of Bifidobacterium and the other strict or facultative anaerobes to ferment TOS in 1% solution was tabulated in Table 1 . All of the Bifidobacterium strains tested, eight reference strains and B. breve 4006 expressed an active growth in TOS medium within 24 hr. On the contrary, none of 55 cultures of other genera showed growth except 2 strains of Bacteroides and 4 strains of Lactobacillus and Enterobac- teriaceae. Since the results showed that TOS was a suitable carbohydrate for growth of bifidobacteria in vitro, we attempted to confirm the non-absorbability of TOS in vivo by using the hydrogen breath test (14) . The mean hydrogen response-time curves of the 5 healthy subjects, arbitarily selected, were presented in Fig. 2 . After the ingestion of 0.5 g of TOS per kilogram body weight by the fasting subjects, the H2 concentrations in the breath samples were determined for the following period of 4 hr by means of gas chromatography. The values of maximum increases in breath hydrogen concentrations above the basal level in fasting subjects were higher than 0.05 ml/min/m2 of body surface in all 5 subjects. These results are comparable with the observation on the lactulose-hydrogen breath test by Nose et al. (14) . Therefore, it is concluded that TOS is metabDlized by intestinal bacteria with the production of hydrogen while it is absorbed very limitedly by the recipient subjects, which is analogous to the case of lactulose.
The feeding experiment: The three feeds studies were conducted as follows.
Group I ; TOS feeding (3 g or 10 g per day), 5 subjects. Details of the dietary manipulations and fecal collection schedules are described in Table 2 .
Bacteriology: One g portion (wet weight) of freshly voided fecal sample were subjected to the test. Medium preparation, dilution et al. number of Bacteroidaceae. The significant decreases in the fecal Bacteroidaceae counts were also observed in group II and III after 2 weeks' ingestion of B. breve 4006 and/or TOS. Enterobacteriaceae count was also decreased in group III who were ingested with B. breve 4006 and TOS. It is conceivable that gram negative anaerobes and aerobes , Bacteroidaceae and Enterobacteriaceae are suppressed by the administration of B. breve 4006 and/or TOS. However, the reason for the decreases in these gram negative bacterial counts remains to be solved with respect to the antagonistic bacterial interactions in the intestinal microbial ecosystem. Other intestinal bacteria: Administration of B. breve 4006 with TOS caused a significant decrease in the total bacterial counts in group III. This was probably due to the reduction of both Bacteroidaceae and Bifidobacterium counts. In contrast, TOS (10 g/ day) caused a significant increase of Lactobacillus counts in group I. The counts of clostridia, streptococci and staphylococci were not or only limitedly changed in all groups tested.
Fecal ammonia and urinary indican excretion: The fecal ammonia level was lowered markedly after the introduction of TOS in 4 of 5 subjects of group III. No apparent changes were observed in the other two groups. The ingestion of TOS also caused significant decreases in the urinary indican excretion in group III, but no apparent dif- for the production of ammonia and indole in vitro (11, 22) . It seems that the reduction of both fecal ammonia and urinary indican excretion were caused by decreased counts of Bacteroidaceae and Enterobacteriaceae due to the administration of B. breve 4006 and TOS. The present results were in accordance with our previous animal studies in which the administration of B. breve 4006 and TOS effected a significant suppression of gram negative bacteria and their putrefactive metabolites in human flora rats (19) . It has been suggested that diet might influence the composition and/or activity of the intestinal bacterial flora, but rather less information is available on this aspect (10) . The present data provide the clear-cut evidence that feeding Bifidobacterium breve 4006 with TOS alter the composition and/or activity of the intestinal bacterial flora to a more favorable one for human health. It might be probable that the present new bifidus factor, TOS, elevates bifidobacteria level in the intestine of bottle-fed infant.
Further work is now in progress to assess the therapeutic application of the co-administration of B. breve 4006 and TOS for constipation (24) and portal-systemic encephalopathy
